5TWY

Structure of Maternal Embryonic Leucine Zipper Kinase


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.91 Å
  • R-Value Free: 0.330 
  • R-Value Work: 0.286 
  • R-Value Observed: 0.288 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

MELK is not necessary for the proliferation of basal-like breast cancer cells.

Huang, H.T.Seo, H.S.Zhang, T.Wang, Y.Jiang, B.Li, Q.Buckley, D.L.Nabet, B.Roberts, J.M.Paulk, J.Dastjerdi, S.Winter, G.E.McLauchlan, H.Moran, J.Bradner, J.E.Eck, M.J.Dhe-Paganon, S.Zhao, J.J.Gray, N.S.

(2017) Elife 6

  • DOI: 10.7554/eLife.26693
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • Thorough preclinical target validation is essential for the success of drug discovery efforts. In this study, we combined chemical and genetic perturbants, including the development of a novel selective maternal embryonic leucine zipper kinase (MELK) ...

    Thorough preclinical target validation is essential for the success of drug discovery efforts. In this study, we combined chemical and genetic perturbants, including the development of a novel selective maternal embryonic leucine zipper kinase (MELK) inhibitor HTH-01-091, CRISPR/Cas9-mediated MELK knockout, a novel chemical-induced protein degradation strategy, RNA interference and CRISPR interference to validate MELK as a therapeutic target in basal-like breast cancers (BBC). In common culture conditions, we found that small molecule inhibition, genetic deletion, or acute depletion of MELK did not significantly affect cellular growth. This discrepancy to previous findings illuminated selectivity issues of the widely used MELK inhibitor OTSSP167, and potential off-target effects of MELK-targeting short hairpins. The different genetic and chemical tools developed here allow for the identification and validation of any causal roles MELK may play in cancer biology, which will be required to guide future MELK drug discovery efforts. Furthermore, our study provides a general framework for preclinical target validation.


    Organizational Affiliation

    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Maternal embryonic leucine zipper kinase
A, B
341Homo sapiensMutation(s): 0 
Gene Names: MELKKIAA0175
EC: 2.7.11.1 (PDB Primary Data), 2.7.10.2 (PDB Primary Data)
Find proteins for Q14680 (Homo sapiens)
Go to UniProtKB:  Q14680
NIH Common Fund Data Resources
PHAROS  Q14680
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
7LY
Query on 7LY

Download CCD File 
A, B
2-(benzyloxy)-4-(1H-pyrazol-4-yl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzamide
C27 H26 N4 O2
CZXJXUACNMVIHE-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.91 Å
  • R-Value Free: 0.330 
  • R-Value Work: 0.286 
  • R-Value Observed: 0.288 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 61.86α = 90
b = 80.02β = 109.95
c = 79.8γ = 90
Software Package:
Software NamePurpose
Aimlessdata scaling
PHENIXrefinement
PDB_EXTRACTdata extraction
PHASERphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2017-11-22
    Type: Initial release
  • Version 1.1: 2019-06-05
    Changes: Data collection, Database references